Raras
Buscar doenças, sintomas, genes...
Encefalopatia mioclônica precoce
ORPHA:1935DOENÇA RARA

Síndrome epiléptica neonatal/infantil caracterizada por convulsões frequentes resistentes a medicamentos que começam ≤3 meses de idade, com EEG interictal e exame neurológico anormais. Em até 80% dos pacientes, o EIDEE é causado por uma razão estrutural, genética ou metabólica subjacente.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Síndrome epiléptica neonatal/infantil caracterizada por convulsões frequentes resistentes a medicamentos que começam ≤3 meses de idade, com EEG interictal e exame neurológico anormais. Em até 80% dos pacientes, o EIDEE é causado por uma razão estrutural, genética ou metabólica subjacente.

Publicações científicas
109 artigos
Último publicado: 2025
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
38 sintomas
🦴
Ossos e articulações
6 sintomas
😀
Face
3 sintomas
📏
Crescimento
3 sintomas
💪
Músculos
3 sintomas
🫃
Digestivo
2 sintomas

+ 26 sintomas em outras categorias

Características mais comuns

Hérnia umbilical
Dedo largo
Testa inclinada
Fissura palatina
Estrabismo
Displasia renal
90sintomas
Sem dados (90)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 90 características clínicas mais associadas, ordenadas por frequência.

Hérnia umbilicalUmbilical hernia
Dedo largoBroad finger
Testa inclinadaSloping forehead
Fissura palatinaCleft palate
EstrabismoStrabismus

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico109PubMed
Últimos 10 anos39publicações
Pico20198 papers
Linha do tempo
2025Hoje · 2026🧪 2000Primeiro ensaio clínico📈 2019Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

21 genes identificados com associação a esta condição.

SLC25A22Mitochondrial glutamate carrier 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial glutamate/H(+) symporter. Responsible for the transport of glutamate from the cytosol into the mitochondrial matrix with the concomitant import of a proton (PubMed:11897791). Plays a role in the control of glucose-stimulated insulin secretion (By similarity)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
SLC-mediated transport of neurotransmittersMalate-aspartate shuttle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 3

A severe form of epilepsy characterized by frequent tonic seizures or spasms beginning in infancy with a specific EEG finding of suppression-burst patterns, characterized by high-voltage bursts alternating with almost flat suppression phases. DEE3 is characterized by a very early onset, erratic and fragmentary myoclonus, massive myoclonus, partial motor seizures and late tonic spasms. The prognosis is poor, with no effective treatment, and children with the condition either die within 1 to 2 years after birth or survive in a persistent vegetative state.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
172.4 TPM
Cérebro - Hemisfério cerebelar
161.2 TPM
Brain Frontal Cortex BA9
119.4 TPM
Córtex cerebral
112.9 TPM
Brain Anterior cingulate cortex BA24
111.3 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 3malignant migrating partial seizures of infancyearly-infantile DEE
HGNC:19954UniProt:Q9H936
SCN1BSodium channel regulatory subunit beta-1Candidate gene tested inModerado
FUNÇÃO

Regulatory subunit of multiple voltage-gated sodium (Nav) channels directly mediating the depolarization of excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient. The influx of Na+ ions provoke

LOCALIZAÇÃO

Cell membranePerikaryonCell projectionCell projection, axonSecreted

VIAS BIOLÓGICAS (3)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisationSensory perception of sweet, bitter, and umami (glutamate) taste
MECANISMO DE DOENÇA

Generalized epilepsy with febrile seizures plus 1

A rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. This disease combines febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
166.3 TPM
Cérebro - Hemisfério cerebelar
165.4 TPM
Músculo esquelético
108.1 TPM
Brain Frontal Cortex BA9
81.3 TPM
Córtex cerebral
67.1 TPM
OUTRAS DOENÇAS (11)
generalized epilepsy with febrile seizures plus, type 1developmental and epileptic encephalopathy, 52Brugada syndrome 5atrial fibrillation, familial, 13
HGNC:10586UniProt:Q07699
ARXHomeobox protein ARXCandidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor (PubMed:22194193, PubMed:31691806). Binds to specific sequence motif 5'-TAATTA-3' in regulatory elements of target genes, such as histone demethylase KDM5C (PubMed:22194193, PubMed:31691806). Positively modulates transcription of KDM5C (PubMed:31691806). Activates expression of KDM5C synergistically with histone lysine demethylase PHF8 and perhaps in competition with transcription regulator ZNF711; synergy may be related to enrichment of histone H3K4me3 in regulatory element

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Lissencephaly, X-linked 2

A classic type lissencephaly associated with abnormal genitalia. Patients have severe congenital or postnatal microcephaly, lissencephaly, agenesis of the corpus callosum, neonatal-onset intractable epilepsy, poor temperature regulation, chronic diarrhea, and ambiguous or underdeveloped genitalia.

OUTRAS DOENÇAS (9)
X-linked lissencephaly with abnormal genitaliaPartington syndromecorpus callosum agenesis-abnormal genitalia syndromedevelopmental and epileptic encephalopathy, 1
HGNC:18060UniProt:Q96QS3
PIGPPhosphatidylinositol N-acetylglucosaminyltransferase subunit PCandidate gene tested inTolerante
FUNÇÃO

Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 55

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE55 is an autosomal recessive condition.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
8.1 TPM
Testículo
7.4 TPM
Brain Spinal cord cervical c-1
7.3 TPM
Glândula adrenal
6.9 TPM
Nervo tibial
6.4 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 55early-infantile DEE
HGNC:3046UniProt:P57054
CASKKappa-caseinCandidate gene tested inAltamente restrito
FUNÇÃO

Kappa-casein stabilizes micelle formation, preventing casein precipitation in milk

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (7)
Assembly and cell surface presentation of NMDA receptorsDopamine Neurotransmitter Release CycleNeurexins and neuroliginsNephrin family interactionsSyndecan interactions
OUTRAS DOENÇAS (4)
FG syndrome 4syndromic X-linked intellectual disability Najm typeearly-infantile DEEnon-syndromic X-linked intellectual disability
HGNC:1497UniProt:P07498
RHOBTB2Rho-related BTB domain-containing protein 2Candidate gene tested inTolerante
FUNÇÃO

Regulator of cell proliferation and apoptosis (PubMed:21801820). It likely functions as a substrate-adapter that recruits key substrates, e.g. MSI2, to CUL3-based ubiquitin ligase complexes for degradation (PubMed:15107402, PubMed:27941885). Required for MSI2 ubiquitination and degradation (PubMed:27941885)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
RHOBTB2 GTPase cycle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 64

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE64 is an autosomal dominant form characterized by onset of seizures usually in the first year of life. Seizure types are variable and include focal dyscognitive and generalized tonic-clonic seizures, as well as febrile seizures in the mildest affected individuals. Seizures tend to respond to medical treatment.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
75.6 TPM
Córtex cerebral
63.2 TPM
Brain Frontal Cortex BA9
60.2 TPM
Brain Caudate basal ganglia
54.5 TPM
Brain Putamen basal ganglia
40.2 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 64alternating hemiplegia of childhoodearly-infantile DEE
HGNC:18756UniProt:Q9BYZ6
CACNA1EVoltage-dependent R-type calcium channel subunit alpha-1ECandidate gene tested inAltamente restrito
FUNÇÃO

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells (PubMed:30343943). They are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1E gives rise to R-type calcium currents. R-type calcium channels belong to the 'high-voltage activated' (HVA) group and are blocked by nickel. They are however insensit

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (2)
Presynaptic depolarization and calcium channel openingRegulation of insulin secretion
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 69

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE69 is an autosomal dominant form characterized by refractory seizures, hypotonia, and profoundly impaired development often associated with macrocephaly, hyperkinetic movements, and contractures. The disorder can sometimes result in early death. Some patients may have a favorable seizure response to topiramate medication.

OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 69early-infantile DEE
HGNC:1392UniProt:Q15878
PNKPBifunctional polynucleotide phosphatase/kinaseCandidate gene tested inTolerante
FUNÇÃO

Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways (PubMed:10446192, PubMed:10446193, PubMed:15385968, PubMed:20852255, PubMed:28453785). Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone (PubMed:10446192, PubMed:10446

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (1)
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
MECANISMO DE DOENÇA

Microcephaly, seizures, and developmental delay

An autosomal recessive neurodevelopmental disorder characterized by infantile-onset seizures, microcephaly, severe intellectual disability and delayed motor milestones with absent speech or only achieving a few words. Most patients also have behavioral problems with hyperactivity. Microcephaly is progressive and without neuronal migration or structural abnormalities, consistent with primary microcephaly.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
66.8 TPM
Tireoide
63.9 TPM
Baço
59.2 TPM
Glândula adrenal
55.9 TPM
Cervix Endocervix
51.8 TPM
OUTRAS DOENÇAS (4)
microcephaly, seizures, and developmental delayataxia - oculomotor apraxia type 4Charcot-Marie-Tooth disease type 2B2early-infantile DEE
HGNC:9154UniProt:Q96T60
KCNA1Potassium voltage-gated channel subfamily A member 1Candidate gene tested inTolerante
FUNÇÃO

Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818, PubMed:8845167). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alte

LOCALIZAÇÃO

Cell membraneMembraneCell projection, axonCytoplasmic vesiclePerikaryonEndoplasmic reticulumCell projection, dendriteCell junctionSynapsePresynaptic cell membranePresynapse

VIAS BIOLÓGICAS (1)
Voltage gated Potassium channels
MECANISMO DE DOENÇA

Episodic ataxia 1

An autosomal dominant disorder characterized by brief episodes of ataxia and dysarthria. Neurological examination during and between the attacks demonstrates spontaneous, repetitive discharges in the distal musculature (myokymia) that arise from peripheral nerve. Nystagmus is absent.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
56.0 TPM
Cerebelo
42.4 TPM
Brain Frontal Cortex BA9
13.3 TPM
Brain Nucleus accumbens basal ganglia
7.8 TPM
Brain Caudate basal ganglia
7.8 TPM
OUTRAS DOENÇAS (5)
episodic ataxia type 1early-infantile DEEepisodic kinesigenic dyskinesiahereditary continuous muscle fiber activity
HGNC:6218UniProt:Q09470
NEUROD2Neurogenic differentiation factor 2Candidate gene tested inTolerante
FUNÇÃO

Transcriptional regulator implicated in neuronal determination. Mediates calcium-dependent transcription activation by binding to E box-containing promoter. Critical factor essential for the repression of the genetic program for neuronal differentiation; prevents the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. Induces transcription of ZEB1, which in turn represses neuronal differentiation by down-regulating REST expression. Plays a

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 72

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE72 is an autosomal dominant form with variable severity and onset in infancy.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
192.0 TPM
Cerebelo
174.4 TPM
Brain Frontal Cortex BA9
40.4 TPM
Córtex cerebral
32.4 TPM
Brain Anterior cingulate cortex BA24
27.8 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 72early-infantile DEE
HGNC:7763UniProt:Q15784
SLC32A1Vesicular inhibitory amino acid transporterCandidate gene tested inAltamente restrito
FUNÇÃO

Antiporter that exchanges vesicular protons for cytosolic 4-aminobutanoate or to a lesser extend glycine, thus allowing their secretion from nerve terminals. The transport is equally dependent on the chemical and electrical components of the proton gradient (By similarity). May also transport beta-alanine (By similarity). Acidification of GABAergic synaptic vesicles is a prerequisite for 4-aminobutanoate uptake (By similarity)

LOCALIZAÇÃO

Cytoplasmic vesicle membranePresynapse

VIAS BIOLÓGICAS (1)
GABA synthesis, release, reuptake and degradation
MECANISMO DE DOENÇA

Generalized epilepsy with febrile seizures plus 12

An autosomal dominant neurologic disorder with variable expressivity and incomplete penetrance. Affected individuals have variable types of seizures, most often febrile seizures, sometimes combined with non-febrile focal or generalized seizures. Rarely, afebrile tonic-clonic seizures have been observed.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Nucleus accumbens basal ganglia
51.3 TPM
Brain Caudate basal ganglia
26.5 TPM
Hipotálamo
16.1 TPM
Cerebelo
15.7 TPM
Brain Putamen basal ganglia
15.7 TPM
OUTRAS DOENÇAS (4)
generalized epilepsy with febrile seizures plus, type 12developmental and epileptic encephalopathy 114early-infantile DEEgeneralized epilepsy with febrile seizures plus
HGNC:11018UniProt:Q9H598
SCN2ASodium channel protein type 2 subunit alphaCandidate gene tested inAltamente restrito
FUNÇÃO

Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient (PubMed:1325650, PubMed:17021166, PubMed:28256214, PubMed:29844171). Implicated in the regulation of hippocampal replay occurring within sharp wave ripples (SPW-R) important for memory (By simi

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisationSensory perception of sweet, bitter, and umami (glutamate) taste
MECANISMO DE DOENÇA

Seizures, benign familial infantile, 3

A form of benign familial infantile epilepsy, a neurologic disorder characterized by afebrile seizures occurring in clusters during the first year of life, without neurologic sequelae. BFIS3 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
70.3 TPM
Cerebelo
65.2 TPM
Brain Frontal Cortex BA9
19.3 TPM
Córtex cerebral
11.5 TPM
Brain Nucleus accumbens basal ganglia
9.1 TPM
OUTRAS DOENÇAS (10)
seizures, benign familial infantile, 3episodic ataxia, type 9developmental and epileptic encephalopathy, 11complex neurodevelopmental disorder
HGNC:10588UniProt:Q99250
GRM7Metabotropic glutamate receptor 7Candidate gene tested inRestrito
FUNÇÃO

G-protein coupled receptor activated by glutamate that regulates axon outgrowth through the MAPK-cAMP-PKA signaling pathway during neuronal development (PubMed:33500274). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase that it inhibits (PubMed:9473604)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
G alpha (i) signalling eventsClass C/3 (Metabotropic glutamate/pheromone receptors)
MECANISMO DE DOENÇA

Neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalities

An autosomal recessive neurodevelopmental disorder characterized by global developmental delay, hypotonia, severe to profound intellectual disability, early-onset epilepsy, and microcephaly. Neuroimaging shows cerebral atrophy, thin corpus callosum and hypomyelination in a majority of cases. Death in childhood may occur.

EXPRESSÃO TECIDUAL(Baixa expressão)
Brain Frontal Cortex BA9
4.9 TPM
Hipotálamo
3.7 TPM
Córtex cerebral
3.1 TPM
Brain Nucleus accumbens basal ganglia
2.7 TPM
Brain Anterior cingulate cortex BA24
2.6 TPM
OUTRAS DOENÇAS (3)
neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalitiesearly-infantile DEEautosomal recessive non-syndromic intellectual disability
HGNC:4599UniProt:Q14831
PIGQPhosphatidylinositol N-acetylglucosaminyltransferase subunit QCandidate gene tested inTolerante
FUNÇÃO

Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Multiple congenital anomalies-hypotonia-seizures syndrome 4

An autosomal recessive syndrome characterized by onset of refractory seizures in the first months of life. Additional clinical features include severe global developmental delay, dysmorphic facial features, and skeletal, renal and ophthalmic anomalies. At the cellular level, the disorder is caused by a defect in the synthesis of glycosylphosphatidylinositol (GPI).

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
53.0 TPM
Testículo
49.5 TPM
Pituitária
41.1 TPM
Rim - Medula
33.3 TPM
Cerebelo
31.1 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 77early-infantile DEE
HGNC:14135UniProt:Q9BRB3
CDKL5Cyclin-dependent kinase-like 5Candidate gene tested inAltamente restrito
FUNÇÃO

Mediates phosphorylation of MECP2 (PubMed:15917271, PubMed:16935860). May regulate ciliogenesis (PubMed:29420175)

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, cilium basal bodyCytoplasm, cytoskeleton, microtubule organizing center, centrosome

OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 2X-linked retinoschisisCDKL5 disorderearly-infantile DEE
HGNC:11411UniProt:O76039
DMXL2DmX-like protein 2Candidate gene tested inAltamente restrito
FUNÇÃO

May serve as a scaffold protein for MADD and RAB3GA on synaptic vesicles (PubMed:11809763). Plays a role in the brain as a key controller of neuronal and endocrine homeostatic processes (By similarity)

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle

MECANISMO DE DOENÇA

Polyendocrine-polyneuropathy syndrome

A progressive endocrine and neurodevelopmental disorder manifesting early in childhood with growth retardation and recurrent episodes of profound asymptomatic hypoglycemia. PEPNS is characterized by central hypothyroidism, hypogonadotropic hypogonadism, incomplete puberty, progressive non-autoimmune insulin-dependent diabetes mellitus, peripheral demyelinating sensorimotor polyneuropathy, and cerebellar and pyramidal signs.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
22.0 TPM
Cerebelo
20.8 TPM
Pituitária
16.6 TPM
Pulmão
14.8 TPM
Testículo
13.9 TPM
OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 81polyendocrine-polyneuropathy syndromehearing loss, autosomal dominant 71early-infantile DEE
HGNC:2938UniProt:Q8TDJ6
GRIN1Glutamate receptor ionotropic, NMDA 1Candidate gene tested inAltamente restrito
FUNÇÃO

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:21376300, PubMed:26875626, PubMed:26919761, PubMed:28126851, PubMed:28228639, PubMed:36959261, PubMed:7679115, PubMed:7681588, PubMed:7685113). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the long-term potentiation (LTP) (PubMed:26875626). Channel

LOCALIZAÇÃO

Cell membranePostsynaptic cell membranePostsynaptic density membraneSynaptic cell membrane

VIAS BIOLÓGICAS (9)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant

An autosomal dominant neurodevelopmental disorder characterized by severe intellectual disability and developmental delay, absent speech, muscular hypotonia, dyskinesia, and hyperkinetic movements. Cortical blindness, cerebral atrophy, and seizures are present in some patients.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
222.8 TPM
Cerebelo
219.9 TPM
Brain Frontal Cortex BA9
191.7 TPM
Cérebro - Hemisfério cerebelar
171.8 TPM
Brain Nucleus accumbens basal ganglia
119.2 TPM
OUTRAS DOENÇAS (7)
neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominantneurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessivedevelopmental and epileptic encephalopathy 101early-infantile DEE
HGNC:4584UniProt:Q05586
GNAO1Guanine nucleotide-binding protein G(o) subunit alphaCandidate gene tested inDesconhecido
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:29925951, PubMed:33408414). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (By similarity). Signaling by an activated GPCR promotes GDP release and GTP binding (By similarity). The alpha subunit has a low GTPase activity that converts bound

LOCALIZAÇÃO

Cell membraneMembrane

VIAS BIOLÓGICAS (1)
Ca2+ pathway
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 17

A severe neurologic disorder characterized by onset of intractable seizures in the first weeks or months of life and usually associated with EEG abnormalities. Affected infants have very poor psychomotor development and may have brain abnormalities, such as cerebral atrophy or thin corpus callosum. Some patients may show involuntary movements.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
92.1 TPM
Cérebro - Hemisfério cerebelar
82.9 TPM
Brain Frontal Cortex BA9
82.9 TPM
Córtex cerebral
79.5 TPM
Brain Caudate basal ganglia
74.3 TPM
OUTRAS DOENÇAS (4)
neurodevelopmental disorder with involuntary movementsdevelopmental and epileptic encephalopathy, 17GNAO1-related developmental delay-seizures-movement disorder spectrumearly-infantile DEE
HGNC:4389UniProt:P09471
TRIM8E3 ubiquitin-protein ligase TRIM8Candidate gene tested inAltamente restrito
FUNÇÃO

E3 ubiquitin-protein ligase that participates in multiple biological processes including cell survival, differentiation, apoptosis, and in particular, the innate immune response (PubMed:27981609, PubMed:28747347). Participates in the activation of interferon-gamma signaling by promoting proteasomal degradation of the repressor SOCS1 (PubMed:12163497). Plays a positive role in the TNFalpha and IL-1beta signaling pathways. Mechanistically, induces the 'Lys-63'-linked polyubiquitination of MAP3K7/T

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nuclear body

VIAS BIOLÓGICAS (1)
Interferon gamma signaling
MECANISMO DE DOENÇA

Focal segmental glomerulosclerosis and neurodevelopmental syndrome

An autosomal dominant disorder characterized by global developmental delay associated with variable features of focal segmental glomerulosclerosis, a renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Some patients have transient proteinuria and others require renal transplant. Neurodevelopmental features are also variable, with some patients having only mildly impaired intellectual development, and others having a severe developmental disorder associated with early-onset refractory seizures or epileptic encephalopathy. Additional features, including feeding difficulties, poor overall growth, and non-specific dysmorphic facial features, are commonly observed.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
178.8 TPM
Cervix Endocervix
158.3 TPM
Tireoide
154.4 TPM
Tecido adiposo
150.5 TPM
Aorta
149.7 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
focal segmental glomerulosclerosis and neurodevelopmental syndromeearly-infantile DEE
HGNC:15579UniProt:Q9BZR9
SLC1A2Excitatory amino acid transporter 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Sodium-dependent, high-affinity amino acid transporter that mediates the uptake of L-glutamate and also L-aspartate and D-aspartate (PubMed:14506254, PubMed:15265858, PubMed:26690923, PubMed:7521911). Functions as a symporter that transports one amino acid molecule together with two or three Na(+) ions and one proton, in parallel with the counter-transport of one K(+) ion (PubMed:14506254). Mediates Cl(-) flux that is not coupled to amino acid transport; this avoids the accumulation of negative

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Astrocytic Glutamate-Glutamine Uptake And MetabolismGlutamate Neurotransmitter Release CycleSLC-mediated transport of amino acids
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 41

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE41 inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Caudate basal ganglia
460.3 TPM
Brain Putamen basal ganglia
378.3 TPM
Brain Anterior cingulate cortex BA24
377.3 TPM
Brain Nucleus accumbens basal ganglia
373.1 TPM
Córtex cerebral
361.7 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 41undetermined early-onset epileptic encephalopathy
HGNC:10940UniProt:P43004
SIK1Serine/threonine-protein kinase SIK1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis regulation, muscle growth and differentiation and tumor suppression. Phosphorylates HDAC4, HDAC5, PPME1, SREBF1, CRTC1/TORC1. Inhibits CREB activity by phosphorylating and inhibiting activity of TORCs, the CREB-specific coactivators, like CRTC2/TORC2 and CRTC3/TORC3 in response to cAMP signaling (PubMed:29211348). Acts as a tumor suppressor and plays a key role in p53/TP53

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 30

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.

EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Not Sun Exposed Suprapubic
14.4 TPM
Skin Sun Exposed Lower leg
10.9 TPM
Ovário
4.6 TPM
Fallopian Tube
4.2 TPM
Tecido adiposo
3.5 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 30early-infantile DEE
HGNC:11142UniProt:P57059

Variantes genéticas (ClinVar)

668 variantes patogênicas registradas no ClinVar.

🧬 SLC25A22: GRCh38/hg38 11p15.5-15.4(chr11:198510-3400939)x3 ()
🧬 SLC25A22: NM_001191061.2(SLC25A22):c.-164+131G>T ()
🧬 SLC25A22: NM_001191061.2(SLC25A22):c.413-70C>T ()
🧬 SLC25A22: NM_001191061.2(SLC25A22):c.4del (p.Ala2fs) ()
🧬 SLC25A22: NM_001191061.2(SLC25A22):c.452C>A (p.Ser151Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1,932 variantes classificadas pelo ClinVar.

1159
773
VUS (60.0%)
Benigna (40.0%)
VARIANTES MAIS SIGNIFICATIVAS
JMJD1C: NM_032776.3(JMJD1C):c.2896C>T (p.Pro966Ser) [Uncertain significance]
JMJD1C: NM_032776.3(JMJD1C):c.3239T>A (p.Met1080Lys) [Uncertain significance]
JMJD1C: NM_032776.3(JMJD1C):c.151C>A (p.Arg51Ser) [Uncertain significance]
KCND2: NM_012281.3(KCND2):c.1349A>T (p.Asn450Ile) [Uncertain significance]
JMJD1C-AS1: NM_032776.3(JMJD1C):c.53C>G (p.Ala18Gly) [Uncertain significance]

Vias biológicas (Reactome)

35 vias biológicas associadas aos genes desta condição.

SLC-mediated transport of neurotransmitters Malate-aspartate shuttle Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation Sensory perception of sweet, bitter, and umami (glutamate) taste SLIT2 gene expression is stimulated by ISL1 Primary multipotent pancreatic progenitor cell produces trunk bipotent pancreatic progenitor cell Synthesis of glycosylphosphatidylinositol (GPI) Miscellaneous transport and binding events RHOBTB2 GTPase cycle Presynaptic depolarization and calcium channel opening Regulation of insulin secretion APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway Voltage gated Potassium channels GABA synthesis, release, reuptake and degradation G alpha (i) signalling events Class C/3 (Metabotropic glutamate/pheromone receptors) Transcriptional Regulation by MECP2 Loss of function of MECP2 in Rett syndrome Regulation of MECP2 expression and activity EPHB-mediated forward signaling Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation Ca2+ pathway Interferon gamma signaling Astrocytic Glutamate-Glutamine Uptake And Metabolism Glutamate Neurotransmitter Release Cycle SLC-mediated transport of amino acids Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Encefalopatia mioclônica precoce

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
40 papers (10 anos)
#1

[Epileptic encephalopathy associated with a mutation in the KCNT1 gene].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2025

According to the World Health Organization, more than 50 million people worldwide have epilepsy, and about 5 million new cases are reported annually. According to other data, the number of patients exceeds 70.000.000, highlighting the relevance of this condition. Studies of developmental epileptic encephalopathies leading to early disability are particularly relevant. About 900 gene mutations associated with different types of epilepsy have been identified so far. One of the prominent «channelopathy genes» representatives is KCNT1, coding the largest subunit of the sodium-activated potassium channel, KNa1.1. Its mutations are associated with many neurological disorders, such as leukodystrophy, leukoencephalopathy, West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, focal epilepsy, and multifocal epilepsy. A clinical case of a typical course of KCNT1-associated epilepsy with early onset (in the first half of life), focal and asynchronous paroxysms, psychomotor retardation, and drug resistance is presented. The effectiveness of the anticonvulsants used and the nature of pharmacological resistance were analyzed. The applicability of four «Drug Resistance Hypotheses» to this case is shown: genetic, since the pathogenesis of this particular case is based on a change in the properties of potassium channels; a change in the sensitivity of the anticonvulsant targets explains the intermittent (according to Schmidt and Löscher) nature of resistance. The «Neural Networks Hypothesis» is illustrated by the change of encephalographic indicators from multifocal epileptiform activity with an intact background to pronounced dysrhythmia with periods of the «burst-suppression» pattern after several months. All these features, combined, refer to the «Intrinsic Severity» hypothesis by Rogawski and Johnson, since the child's disease was initially severe due to the intensity and frequency of epileptic seizures. As a result, a conclusion was made about the complexity of the refractoriness formation mechanisms, even in cases with a simple and understandable pathogenesis of channelopathy. По данным Всемирной организации здравоохранения, эпилепсией страдают более 50 млн человек во всем мире и ежегодно около 5 млн человек узнают об этом диагнозе. По другим данным, число больных превышает 70 млн, что определяет и долго еще будет определять актуальность любого материала по этой тематике. Особенно актуальны исследования эпилептических энцефалопатий развития, приводящих к ранней инвалидизации. В настоящее время насчитывают около 900 генов, различные мутации которых объясняют появление различных типов эпилепсий. Одним из ярких представителей «генов каналопатий» является KCNT1, детерминирующий самую большую субъединицу активируемого натрием калиевого канала — KNa1.1. Мутации в нем ассоциированы с большим количеством неврологических расстройств, таких как лейкодистрофия, лейкоэнцефалопатия, синдром Веста, синдром Отахары, ранняя миоклоническая энцефалопатия, фокальная эпилепсия и мультифокальная эпилепсия. Приведен клинический случай типичного течения KCNT1-ассоциированной эпилепсии с ранним, в 1-м полугодии жизни, дебютом, фокальными и асинхронными пароксизмами, задержкой психомоторного развития и фармрезистентностью. Проведен анализ эффективности применявшихся противоэпилептических препаратов (ПЭП) и природы фармакологической резистентности. Показана применимость к данному случаю четырех гипотез фармакорезистентности: генетической; поскольку патогенез данного конкретного случая основан на изменении свойств калиевых каналов, изменением чувствительности «целей» воздействия ПЭП, т.е. «целевой» гипотезой объясняется интермиттирующий характер резистентности. Гипотезу «нейронных сетей» иллюстрирует динамика энцефалографических показателей от мультифокальной эпилептиформной активности при неизмененном фоне до выраженной дизритмии с периодами паттерна «burst-supression» по прошествии нескольких месяцев. Все упомянутые особенности, объединяясь, относятся к гипотезе «внутренней серьезности» Rogavski и Johnson, поскольку заболевание ребенка изначально отличалось тяжестью за счет интенсивности и частоты эпилептических приступов. В итоге делается вывод о сложности механизмов формирования рефрактерности даже в случаях с простым и понятным патогенезом каналопатии.

#2

Association between phenotypes and genotype of developmental and epileptic encephalopathy in next-generation sequencing methods in infants: A scoping review.

The Medical journal of Malaysia2025 Jul

Developmental and epileptic encephalopathy (DEE) is epilepsy related to developmental impairment that may be caused by both the underlying etiology (developmental encephalopathy) and superimposed epileptic activity (epileptic encephalopathy). The origin of DEE and the causes of its variations remain unknown. Owing the lack of clarity regarding the role of genetic variables in DEE, we conducted a scoping review to qualitatively identify the genes most important in the development of DEE to provide an up-to-date review. We searched all published studies related to the genetic factors of DEE. The identified publications were screened and selected by the authors on basis of on inclusion and exclusion criteria and assessed for methodological quality. Eighteen articles were included. The extracted data included age of onset, sex, gene mutations and inheritance (e.g. nucleotide change, protein change, and family testing), clinical manifestation, electroencephalogram, imaging, medication, and outcomes. A total of 18 studies were included in this scoping review. The most frequently reported gene variants were STXBP1 in Ohtahara Syndrome, SLC1A2 in Early Myoclonic Encephalopathy (EME), CDKL5 in West Syndrome, SCN1A in Dravet Syndrome, and KCNT1 in Epilepsy of Infancy with Migrating Focal Seizures (EIMFS). Each gene was associated with distinct electroclinical features, including differences in age of onset, seizure type, EEG patterns, and developmental outcomes. While genotype and phenotype associations were heterogeneous, certain variants showed consistent patterns indicative of more severe disease courses. This review identified key gene variants commonly associated with early-onset DEE in infants, particularly STXBP1, SLC1A2, CDKL5, SCN1A, and KCNT1, each linked to unique clinical presentations and outcomes. These findings support the clinical utility of next-generation sequencing (NGS) for early diagnosis and tailored treatment planning in DEE. Understanding genotype-phenotype correlations may enhance prognostication and highlight potential avenues for targeted therapy in future research.

#3

Metabolic causes of pediatric developmental & epileptic encephalopathies (DEE)- genetic variant analysis in a south Indian cohort.

Seizure2024 Feb

Drug-resistant epilepsy is seen in patients with inborn errors of metabolism and metabolic dysfunction in neurons is crucial to brain disorders associated with psychomotor impairment. Diagnostic rates of metabolic causes of developmental and epileptic encephalopathy (DEE) using next generation sequencing have been rarely studied in literature. A prospective hospital study was carried out in 384 children with DEE, who underwent genetic testing. Metabolic disorders were evaluated with biochemical blood/urine assays and when required CSF estimations performed. A total of 154 pathogenic/likely pathogenic variants in 384 children were identified. Out of 384 children, 89 were clinically suspected to have probable or possible metabolic disorders. Pathogenic/likely pathogenic variants in metabolic genes were identified in 39 out of 89 (43.8 %) and promising VUS in 28 (31.4 %). These included variants for progressive myoclonus epilepsies (21; 53.8 %), DEE with focal/multifocal seizures (8; 20.5 %), generalized epilepsy (5;12.8 %), early myoclonic encephalopathy (2; 5.1 %), LGS (1; 2.6 %) and West syndrome (2; 5.1 %). Our cohort demonstrates for the first time from the Indian subcontinent that identification of metabolic variants can guide investigations and has therapeutic implications in patients with variable DEE phenotypes. A high utility is noted with regard to diagnosis and prognostication, given the low yield of available biochemical tests, indicating cost-effectiveness of this approach.

#4

Comment: Amenable Treatable Severe Pediatric Epilepsies.

Seminars in pediatric neurology2023 Oct

Phillip L. Pearl Seminars in Pediatric Neurology Volume 23, Issue 2, May 2016, Pages 158-166 Vitamin-dependent epilepsies and multiple metabolic epilepsies are amenable to treatment that markedly improves the disease course. Knowledge of these amenably treatable severe pediatric epilepsies allows for early identification, testing, and treatment. These disorders present with various phenotypes, including early onset epileptic encephalopathy (refractory neonatal seizures, early myoclonic encephalopathy, and early infantile epileptic encephalop athy), infantile spasms, or mixed generalized seizure types in infancy, childhood, or even adolescence and adulthood. The disorders are presented as vitamin responsive epilepsies such as pyridoxine, pyridoxal-5-phosphate, folinic acid, and biotin; transportopathies like GLUT-1, cerebral folate deficiency, and biotin thiamine responsive disorder; amino and organic acidopathies including serine synthesis defects, creatine synthesis disorders, molybdenum cofactor deficiency, and cobalamin deficiencies; mitochondrial disorders; urea cycle disorders; neurotransmitter defects; and disorders of glucose homeostasis. In each case, targeted intervention directed toward the underlying metabolic pathophysiology affords for the opportunity to significantly effect the outcome and prognosis of an otherwise severe pediatric epilepsy.

#5

Monoamine neurotransmitters in early epileptic encephalopathies: New insights into pathophysiology and therapy.

Developmental medicine and child neurology2022 Jul

To study neurotransmitter status in children with early epileptic and developmental and epileptic encephalopathy (DEE) and to explore the clinical response to dopaminergic and serotoninergic therapies in a group of patients. Two hundred and five patients (111 males [54.1.%] and 94 females [45.9%], mean age 10 months at the onset of epilepsy [SD 1 year 1 month], range 0-3 year) with epileptic encephalopathy/DEE were recruited, including those with West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, myoclonic encephalopathy in non-progressive disorders, infantile spasms, Doose syndrome, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and those unclassified. Cerebrospinal fluid (CSF) neurotransmitter studies and patients' medical records were reviewed. Additionally, we present clinical data of 10 patients with low CSF neurotransmitter levels who received dopaminergic/serotoninergic treatments. Abnormal neurotransmitter values were identified in 68 (33%) patients. 5-Hydroxyindoleacetic acid (5-HIAA) deficit was the most prevalent alteration (91%). Low CSF 5-HIAA levels were significantly higher in 1- to 3-year-old children. A negative significant correlation was found between 5-HIAA levels and epilepsy duration before CSF study (Spearman's ρ=-0.191, p=0.007). Abnormalities in deep grey matter were associated with low levels of CSF homovanillic acid and 5-HIAA. Ten patients with low CSF neurotransmitter levels received dopamine and/or serotonin therapies. Six of them showed initial decrease of seizure frequency and severity and maintained improvement in some neurodevelopmental skills. A considerable number of patients showed neurotransmitter abnormalities. Age at seizure onset and duration of epilepsy before CSF study were the principal factors related to neurotransmitter depletion. Early monoamine supplementation would seem advisable as a neuroprotective strategy. 5-Hydroxyindoleacetic acid homeostasis is especially vulnerable in patients with epileptic encephalopathy/developmental and epileptic encephalopathy. Age of seizure onset and duration of epilepsy are determinants of neurotransmitter depletion.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC39 artigos no totalmostrando 37

2025

[Epileptic encephalopathy associated with a mutation in the KCNT1 gene].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

Association between phenotypes and genotype of developmental and epileptic encephalopathy in next-generation sequencing methods in infants: A scoping review.

The Medical journal of Malaysia
2024

Metabolic causes of pediatric developmental & epileptic encephalopathies (DEE)- genetic variant analysis in a south Indian cohort.

Seizure
2022

SCN1B Genetic Variants: A Review of the Spectrum of Clinical Phenotypes and a Report of Early Myoclonic Encephalopathy.

Children (Basel, Switzerland)
2022

[Epileptic encephalopathies of onset in neonates and infants].

Medicina
2022

Monoamine neurotransmitters in early epileptic encephalopathies: New insights into pathophysiology and therapy.

Developmental medicine and child neurology
2022

Complementing the phenotypical spectrum of TUBA1A tubulinopathy and its role in early-onset epilepsies.

European journal of human genetics : EJHG
2021

Neonatal Seizures: An Overview of Genetic Causes and Treatment Options.

Brain sciences
2021

Epilepsy Syndromes in the First Year of Life and Usefulness of Genetic Testing for Precision Therapy.

Genes
2021

The relationship between the characteristics of burst suppression pattern and different etiologies in epilepsy.

Scientific reports
2020

A term neonate with early myoclonic encephalopathy caused by RARS2 gene variants: a case report.

Translational pediatrics
2020

Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.

Epilepsy research
2020

Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern.

Epilepsy research
2019

Neonatal Developmental and Epileptic Encephalopathies.

Seminars in pediatric neurology
2019

[Genetically determined epileptic encephalopathies].

Medicina
2020

Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.

Brain & development
2019

Genetics of neonatal-onset epilepsies.

Handbook of clinical neurology
2019

Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo SCN1A mutation.

Seizure
2020

Genetics of neonatal onset epilepsies: An overview.

Revue neurologique
2019

A case of early myoclonic encephalopathy with intractable seizures successfully treated with high-dose phenobarbital.

Brain & development
2019

Different types of suppression-burst patterns in patients with epilepsy of infancy with migrating focal seizures (EIMFS).

Seizure
2019

Ketogenic diet, a potentially valuable therapeutic option for the management of refractory epilepsy in classical neonatal nonketotic hyperglycinemia: a case report.

European journal of clinical nutrition
2018

Epilepsy in Biotinidase Deficiency Is Distinct from Early Myoclonic Encephalopathy.

Neuropediatrics
2018

Early-onset epileptic encephalopathy with myoclonic seizures related to 9q33.3-q34.11 deletion involving STXBP1 and SPTAN1 genes.

Epileptic disorders : international epilepsy journal with videotape
2018

Benign and severe early-life seizures: a round in the first year of life.

Italian journal of pediatrics
2018

Ketogenic Diet Therapy in Infants: Efficacy and Tolerability.

Pediatric neurology
2018

A patient with early myoclonic encephalopathy (EME) with a de novo KCNQ2 mutation.

Brain & development
2017

Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression.

Annals of neurology
2017

A de novo missense mutation of GABRB2 causes early myoclonic encephalopathy.

Journal of medical genetics
2016

Amenable Treatable Severe Pediatric Epilepsies.

Seminars in pediatric neurology
2016

The Expanding Clinical Spectrum of Genetic Pediatric Epileptic Encephalopathies.

Seminars in pediatric neurology
2016

[Vigabatrin administration for infants and young children with intractable generalized epilepsy].

No to hattatsu = Brain and development
2016

Current understanding and neurobiology of epileptic encephalopathies.

Neurobiology of disease
2016

A novel AMT gene mutation in a newborn with nonketotic hyperglycinemia and early myoclonic encephalopathy.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2016

Diagnostic Approach to Genetic Causes of Early-Onset Epileptic Encephalopathy.

Journal of child neurology
2015

De novo mutations in SIK1 cause a spectrum of developmental epilepsies.

American journal of human genetics
2015

Early myoclonic encephalopathy in 9q33-q34 deletion encompassing STXBP1 and SPTAN1.

Annals of human genetics
Ver todos os 39 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Encefalopatia mioclônica precoce.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Encefalopatia mioclônica precoce

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. [Epileptic encephalopathy associated with a mutation in the KCNT1 gene].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova· 2025· PMID 41283838mais citado
  2. Association between phenotypes and genotype of developmental and epileptic encephalopathy in next-generation sequencing methods in infants: A scoping review.
    The Medical journal of Malaysia· 2025· PMID 40740097mais citado
  3. Metabolic causes of pediatric developmental & epileptic encephalopathies (DEE)- genetic variant analysis in a south Indian cohort.
    Seizure· 2024· PMID 38183824mais citado
  4. Comment: Amenable Treatable Severe Pediatric Epilepsies.
    Seminars in pediatric neurology· 2023· PMID 37919041mais citado
  5. Monoamine neurotransmitters in early epileptic encephalopathies: New insights into pathophysiology and therapy.
    Developmental medicine and child neurology· 2022· PMID 35833444mais citado
  6. SCN1B Genetic Variants: A Review of the Spectrum of Clinical Phenotypes and a Report of Early Myoclonic Encephalopathy.
    Children (Basel)· 2022· PMID 36291443recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:1935(Orphanet)
  2. MONDO:0800491(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Encefalopatia mioclônica precoce
Compêndio · Raras BR

Encefalopatia mioclônica precoce

ORPHA:1935 · MONDO:0800491
MedGen
UMLS
C0270855
EuropePMC
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades